Acurx Pharmaceuticals (NASDAQ:ACXP) Posts Earnings Results, Misses Expectations By $0.11 EPS

Acurx Pharmaceuticals (NASDAQ:ACXP) posted its quarterly earnings data on Thursday. The company reported ($0.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.11), FiscalAI reports.

Here are the key takeaways from Acurx Pharmaceuticals’ conference call:

• Acurx began enrolling patients in its fully funded, 20-patient PATHFINDER trial for multiply recurrent C. difficile infection in September. Management expects an enrollment update after completion, potentially in the second half of 2027.
• The FDA is open to further discussion of whether data from PATHFINDER and the planned ASPIRE Phase III study could support an NDA; it has not confirmed an approval pathway. Depending on PATHFINDER results and funding, Acurx may pursue a follow-on recurrent-infection trial under the LPAD pathway, while continuing to consider ASPIRE.
• Acurx ended the quarter with $9.7 million in cash and said it has 12 months of funds, which management believes can cover PATHFINDER if enrollment is completed by the third quarter of 2027. The company may need additional financing through equity or other sources, and reported a quarterly net loss of $2.6 million, up from $2.0 million a year earlier.
• Management said partnering discussions are active but none are at a stage for public disclosure, and it is pursuing grants and other funding for its Phase III program. The company’s proposed PATHFINDER 2 could involve about 350 patients and take 18–24 months to enroll, but its design, cost, and regulatory prospects remain uncertain.

Acurx Pharmaceuticals Price Performance

Acurx Pharmaceuticals stock traded down $0.03 during trading hours on Thursday, hitting $1.00. 111,328 shares of the stock traded hands, compared to its average volume of 962,296. The firm’s 50 day moving average price is $1.23 and its 200-day moving average price is $1.92. The stock has a market capitalization of $5.59 million, a price-to-earnings ratio of -0.37 and a beta of -2.08. Acurx Pharmaceuticals has a 1 year low of $0.95 and a 1 year high of $7.54.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the company. Weiss Ratings restated a “sell (e+)” rating on shares of Acurx Pharmaceuticals in a research note on Thursday, October 15th. HC Wainwright reaffirmed a “buy” rating on shares of Acurx Pharmaceuticals in a research report on Tuesday, September 29th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold”.

About Acurx Pharmaceuticals

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) is a clinical-stage biopharmaceutical company focused on developing novel antibiotics for serious bacterial infections. The company’s research is centered on therapies designed to address pathogens that are resistant to existing treatments. Acurx’s lead product candidate is ibezapolstat, also known as ACX-375, an investigational oral antibiotic being developed for the treatment of Clostridioides difficile infection, commonly known as C. difficile infection.